A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia.
- 1 June 1997
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 11 (6) , 550-565
- https://doi.org/10.2165/00019053-199711060-00004
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Benign Prostatic HyperplasiaDrugs, 1994
- Annual Costs of Benign Prostatic Hyperplasia in New ZealandPharmacoEconomics, 1993
- Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study GroupArchives of Family Medicine, 1993
- Medical Treatment of Benign Prostatic Hyperplasia: 5α-Reductase Inhibitors and α-Adrenergic AntagonistsMayo Clinic Proceedings, 1993
- Economic Burden of Treated Benign Prostatic Hyperplasia in the United KingdomBritish Journal of Urology, 1993
- Doxazosin Treatment in Patients with Prostatic ObstructionScandinavian Journal of Urology and Nephrology, 1993
- A 12‐Week Placebo‐controlled Double‐blind Study of Prazosin in the Treatment of Prostatic Obstruction due to Benign Prostatic HyperplasiaBritish Journal of Urology, 1992
- Principles of Pharmacoeconomic Analysis of Drug TherapyPharmacoEconomics, 1992
- Efficacy and Side-Effects of Prazosin as a Symptomatic Treatment of Benign Prostatic ObstructionScandinavian Journal of Urology and Nephrology, 1991
- Prazosin in the Treatment of Prostatic Obstruction A Placebo‐controlled StudyBritish Journal of Urology, 1987